Arcutis Biotherapeutics, Inc. (ARQT)
ARQTNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$28.22
+0.8300 (+3.03%) today
Regular session, Nov 11, 1:53 PM ET
- Market cap
- $3.57bn
- P/E
- 134.4
- EPS, last 4 quarters
- $0.2100
- Dividend yield
- –
- Day range
- $27.20 to $28.65
- 52-week range
- $19.30 to $34.80
- Average volume
- 2.84m
- Previous close
- $27.39
Analysts
6 coveringBuy5 buy, 1 hold, 0 sell
Targets a year out average $42.00, +48.9% from here
Earnings
next estimate $0.2100Next report
Dec 2025
+333.3%
Mar 2026
-350.0%
Jun 2026
+22.2%
Sep 2026
-64.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $129.50m | $105.40m | $129.86m | $143.92m |
| Gross profit | $117.81m | $95.61m | $118.92m | $131.46m |
| Operating income | $18.39m | -$9.09m | $16.43m | $9.44m |
| Net income | $17.39m | -$11.29m | $15.01m | $8.80m |
Last four quarters: revenue $508.68m, margin 5.9%, free cash flow –
News
8 latest- Arcutis (ARQT) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- Arcutis Biotherapeutics, Inc. Reports Q3 2026 Net Product Revenues of $143.9 million and Raises Full-Year Guidance to $535 million–$545 millionFintel · 7 days ago
- Arcutis Biotherapeutics Q3 Earnings Call HighlightsMarketBeat · 7 days ago
- Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings EstimatesZacks · 7 days ago
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Zacks · Oct 29, 2026
- Arcutis Biotherapeutics, Inc. Appoints Dr. Robert Scott to Board of DirectorsFintel · Oct 28, 2026
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 28, 2026
- Cantor Fitzgerald Initiates Coverage of Arcutis Biotherapeutics at OverweightFintel · Oct 15, 2026
The company
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis' unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- arcutis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.